<DOC>
	<DOCNO>NCT01451398</DOCNO>
	<brief_summary>Insulin-naive subject Type 2 Diabetes Mellitus sub-optimally control either maximum tolerate dose metformin maximum tolerate dose metformin plus one two oral anti-diabetic medication either Prandial Technosphere® Insulin Technosphere Powder ( placebo ) add oral antidiabetic drug .</brief_summary>
	<brief_title>Comparison Technosphere® Insulin Versus Technosphere Powder ( Placebo ) Insulin-Naive Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>HbA1c &gt; = 7.5 % &lt; = 10.0 % Body mass index ( BMI ) &lt; = 45 kg/m2 Non smoker least 6 month Screening Clinical diagnosis type 2 diabetes mellitus 12 month Currently receive diabetes treatment metformin 2 OADs stable dos least 3 month enrollment Subjects receive metformin must least 1.5gm daily , maximum tolerate dose Subjects treat sulfonylurea must least 50 % total maximum approve dose give agent Subjects receive DPP4 inhibitor must receive maximum approve dose specific agent Metiglinide alphaglucoside inhibitor must take high tolerate dose within approve dose range No previous current treatment insulin , except acute illness , gestational diabetes , time initial diagnosis diabetes Forced expiratory volume one second ( FEV1 ) &gt; = 70 % Third National Health Nutrition Examination Survey ( NHANES III ) predict Forced vital capacity ( FVC ) &gt; = 70 % NHANES III predict Forced expiratory volume one second percentage force vital capacity ( FEV1/FVC ) &gt; = NHANES III low limit normal ( LLN ) History chronic obstructive pulmonary disease ( COPD ) , clinically proven asthma , clinically important pulmonary disease ( eg , pulmonary fibrosis ) Any clinically significant radiological finding screen chest xray Use medication asthma , COPD , chronic respiratory condition Evidence serious complication diabetes ( proliferative retinopathy , autonomic neuropathy symptom gastroparesis cardiac arrhythmia ; sensory neuropathy make manipulation Gen2C inhaler difficult ) Renal disease renal dysfunction Significant cardiovascular dysfunction history thereof within 12 month screen ; serious arrhythmia , treatment medication control/treat arrhythmia ; myocardial infarction ; cardiac surgery ; history valvular heart disease Previous current use amiodarone Treatment glucagonlike peptide1 ( GLP1 ) analog , thiazolidinediones ( TZD ) , weight loss drug ( eg , sibutramine , orlistat ) within 3 month screen History pulmonary embolism deep venous thrombosis 12 month Screening History recent blood transfusion ( within previous 3 month ) diagnosis hemoglobinopathy may affect HbA1c measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>